21 Jul 2014
PrimeVigilance was awarded a 2014 Queen’s Award for Enterprise

Ergomed plc announces that its drug safety business PrimeVigilance was awarded a 2014 Queen’s Award
for Enterprise

London, UK – 21 July 2014; Ergomed plc, a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, is pleased to announce that its drug safety business PrimeVigilance, the specialist pharmacovigilance service provider, has been awarded the Queen’s Award for Enterprise 2014 in Recognition of Substantial Growth and Commercial Success. Dr Miro Reljanovic, CEO of Ergomed and Dr Elliot Brown co-founder of PrimeVigilance, collected the award from the Queen at Buckingham Palace on 14 July 2014.

PrimeVigilance received the accolade – which is the highest official award for business success in the UK – in recognition of achieving substantial overseas earnings with growth and commercial success for the last six years.
Dr Miroslav Reljanovic, Chief Executive Officer of Ergomed, commented: “This award is testament to the high quality service we provide to our customers around the world. The Queen’s Award is a great honour not just for the company but for all of our individual employees internationally who have helped contribute to the company’s success. We look forward to building on our success and achieving further growth in the future.”
The Queen’s Awards for Enterprise is a prestigious awards programme for British businesses and organisations that excel at trade, innovation or sustainable development. The awards are made annually by HM The Queen, and are only given for the highest levels of excellence demonstrated in each category. They are judged to a demanding level and winners receive a number of benefits and worldwide recognition.


Dr Reljanovic Queen’s Award

About Ergomed

Founded in 1997, Ergomed Plc is a profitable UK-based company, providing drug development services to the pharmaceutical industry and has a growing portfolio of co-development partnerships. It operates in over 40 countries.
Ergomed provides clinical development, trial management and pharmacovigilance services to over 60 clients ranging from top 10 pharmaceutical companies to small and mid-sized drug development companies. Ergomed successfully manages clinical development from Phase I through to late phase programmes.
Ergomed has a wide therapeutic focus, with a particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed and the physicians involved in clinical trials.
As well as providing high quality clinical development services, Ergomed is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed leverages its expertise and services in return for carried interest in the drugs under development.


About PrimeVigilance
The pharmacovigilance (PV) services offered by PrimeVigilance cover all the regulatory and scientific elements of PV required to obtain and maintain product licences for medicines within Europe: Qualified Person, Risk Management Planning (RMP), and a compliant PV System with consistent Adverse Event data capture, robust Quality Management, expedited reporting, preparation of Periodic Safety Update Reports, literature screening, safety signal detection and evaluation, benefit-risk assessment, compliance auditing, support during crisis and various ad hoc assignments. PrimeVigilance also offers fully integrated international Medical Information services. www.primevigilance.com

For further information:
Hume Brophy
Mary Clark, Supriya Mathur, Hollie Vile
Phone: + 44 203 440 5654
E-mail: healthcareteam@humebrophy.com